PMID

Data

Article Title

Organization

Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.

Amgen

Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate.

Monash University (Parkville Campus)

Synthesis and biological evaluation of chalcones as inhibitors of the voltage-gated potassium channel Kv1.3.

The Walter and Eliza Hall Institute of Medical Research

Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.

Abbott Laboratories

Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2.

Glaxosmithkline

N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1.

Glaxosmithkline

Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.

Wyeth Research

4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.

University of California

 

The SAR of UK-78,282: A novel blocker of human T cell Kv1.3 potassium channels

TBA

Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.

4Sc

Gamma-pyrone natural products--a privileged compound class provided by nature.

Institute of Molecular Physiology

Jatrophane Diterpenoids with Kv1.3 Ion Channel Inhibitory Effects from

Huazhong University of Science and Technology

Potent Kv1.3 inhibitors from correolide-modification of the C18 position.

Merck Research Laboratories

Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.

Institute of Medical Research Biotechnology Centre

Benzamide derivatives as blockers of Kv1.3 ion channel.

Merck Research Laboratories

Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.

Aventis Pharma Deutschland

Blockers of human T cell Kv1.3 potassium channels using de novo ligand design and solid-phase parallel combinatorial chemistry.

University of California

Novel inhibitors of potassium ion channels on human T lymphocytes.

Sanofi Winthrop

Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels.

University of Ljubljana